Chibro-Proscar en es it fr

Chibro-Proscar Brand names, Chibro-Proscar Analogs

Chibro-Proscar Brand Names Mixture

  • No information avaliable

Chibro-Proscar Chemical_Formula


Chibro-Proscar RX_link

Chibro-Proscar fda sheet

Chibro-Proscar FDA

Chibro-Proscar msds (material safety sheet)

Chibro-Proscar Synthesis Reference

No information avaliable

Chibro-Proscar Molecular Weight

372.544 g/mol

Chibro-Proscar Melting Point

252-254 oC

Chibro-Proscar H2O Solubility

11.7 mg/L

Chibro-Proscar State


Chibro-Proscar LogP


Chibro-Proscar Dosage Forms


Chibro-Proscar Indication

For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostat.

Chibro-Proscar Pharmacology

Finasteride is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only. Finasteride is a competitive and specific inhibitor of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into DHT. Two distinct isozymes are found in mice, rats, monkeys, and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and developmental stages. In humans, Type I 5a-reductase is predominant in the sebaceous glands of most regions of skin, including scalp, and liver. Type I 5a-reductase is responsible for approximately one-third of circulating DHT. The Type II 5a-reductase isozyme is primarily found in prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT.

Chibro-Proscar Absorption

No information avaliable

Chibro-Proscar side effects and Toxicity

No information avaliable

Chibro-Proscar Patient Information

No information avaliable

Chibro-Proscar Organisms Affected

Humans and other mammals